Virtu Financial LLC Takes Position in Savara Inc (NASDAQ:SVRA)

Virtu Financial LLC purchased a new position in Savara Inc (NASDAQ:SVRA) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 15,853 shares of the company’s stock, valued at approximately $67,000.

A number of other hedge funds also recently bought and sold shares of SVRA. Barclays PLC raised its position in Savara by 217.5% during the third quarter. Barclays PLC now owns 231,005 shares of the company’s stock worth $979,000 after acquiring an additional 158,244 shares during the period. Teachers Retirement System of The State of Kentucky increased its stake in shares of Savara by 148.0% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 132,425 shares of the company’s stock worth $561,000 after purchasing an additional 79,022 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Savara by 10.8% during the 3rd quarter. Geode Capital Management LLC now owns 2,726,850 shares of the company’s stock worth $11,564,000 after purchasing an additional 264,825 shares during the last quarter. Wellington Management Group LLP lifted its stake in Savara by 22.9% in the 3rd quarter. Wellington Management Group LLP now owns 8,624,012 shares of the company’s stock valued at $36,566,000 after buying an additional 1,608,522 shares in the last quarter. Finally, State Street Corp boosted its holdings in Savara by 15.7% in the 3rd quarter. State Street Corp now owns 4,138,276 shares of the company’s stock worth $17,546,000 after buying an additional 560,242 shares during the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Insider Activity

In related news, CEO Matthew Pauls sold 54,702 shares of the firm’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $3.31, for a total transaction of $181,063.62. Following the completion of the sale, the chief executive officer now directly owns 1,536,379 shares of the company’s stock, valued at approximately $5,085,414.49. This trade represents a 3.44 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Joseph S. Mccracken bought 20,000 shares of the firm’s stock in a transaction on Tuesday, November 19th. The stock was bought at an average cost of $2.95 per share, for a total transaction of $59,000.00. Following the transaction, the director now directly owns 210,837 shares of the company’s stock, valued at $621,969.15. The trade was a 10.48 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 5.13% of the company’s stock.

Savara Price Performance

NASDAQ SVRA opened at $3.23 on Friday. The business’s fifty day simple moving average is $3.47 and its 200-day simple moving average is $3.99. The company has a quick ratio of 17.70, a current ratio of 17.70 and a debt-to-equity ratio of 0.13. The firm has a market cap of $554.33 million, a PE ratio of -7.51 and a beta of 0.92. Savara Inc has a 52 week low of $2.82 and a 52 week high of $5.70.

Savara (NASDAQ:SVRA) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.11). As a group, equities analysts anticipate that Savara Inc will post -0.45 earnings per share for the current year.

Wall Street Analyst Weigh In

SVRA has been the subject of a number of research analyst reports. HC Wainwright decreased their target price on Savara from $10.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. JMP Securities reissued a “market outperform” rating and issued a $9.00 price objective on shares of Savara in a research note on Thursday. Evercore ISI reaffirmed an “in-line” rating and set a $5.00 target price (down previously from $7.00) on shares of Savara in a research note on Wednesday, November 13th. Finally, Wells Fargo & Company started coverage on shares of Savara in a research report on Friday. They issued an “overweight” rating and a $8.00 target price for the company. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $9.86.

Savara Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.